## **Supplemental Data for**

## Humoral immune responses to COVID-19 vaccination in people living with HIV on suppressive antiretroviral therapy

Zabrina L. Brumme<sup>1,2\*</sup>, Francis Mwimanzi<sup>1</sup>, Hope R. Lapointe<sup>2</sup>, Peter Cheung<sup>1,2</sup>, Yurou Sang<sup>1</sup>, Maggie C. Duncan<sup>1,2</sup>, Fatima Yaseen<sup>3</sup>, Olga Agafitei<sup>1</sup>, Siobhan Ennis<sup>1</sup>, Kurtis Ng<sup>1</sup>, Simran Basra<sup>1,3,4</sup>, Li Yi Lim<sup>1,3</sup>, Rebecca Kalikawe<sup>1</sup>, Sarah Speckmaier<sup>2</sup>, Nadia Moran-Garcia<sup>2</sup>, Landon Young<sup>5</sup>, Hesham Ali<sup>6</sup>, Bruce Ganase<sup>7</sup>, Gisele Umviligihozo<sup>1</sup>, F. Harrison Omondi<sup>1,2</sup>, Kieran Atkinson<sup>2</sup>, Hanwei Sudderuddin<sup>2,8</sup>, Junine Toy<sup>2</sup>, Paul Sereda<sup>2</sup>, Laura Burns<sup>9</sup>, Cecilia T. Costiniuk<sup>10</sup>, Curtis Cooper<sup>11,12</sup>, Aslam H. Anis<sup>13,14,15</sup>, Victor Leung<sup>5,16</sup>, Daniel Holmes<sup>9,16</sup>, Mari L. DeMarco<sup>9,16</sup>, Janet Simons<sup>9,16</sup>, Malcolm Hedgcock<sup>17</sup>, Marc G. Romney<sup>5,16</sup>, Rolando Barrios<sup>2,13</sup>, Silvia Guillemi<sup>2,18</sup>, Chanson J. Brumme<sup>2,8</sup>, Ralph Pantophlet<sup>1,3</sup>, Julio S.G. Montaner<sup>2,8</sup>, Masahiro Niikura<sup>1</sup>, Marianne Harris<sup>2,18</sup>, Mark Hull<sup>2,8</sup>, Mark A. Brockman<sup>1,2,3\*</sup>

## **Corresponding Author Contact Information:**

Zabrina L. Brumme, Ph.D. Professor, Faculty of Health Sciences Simon Fraser University 8888 University Drive Burnaby, BC, Canada, V5A 1S6

Tel: 778 782-8872 Fax: 778-782-5927

email: zbrumme@sfu.ca; zbrumme@bccfe.ca

<sup>&</sup>lt;sup>1</sup> Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;

<sup>&</sup>lt;sup>2</sup> British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada;

<sup>&</sup>lt;sup>3</sup> Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada;

<sup>&</sup>lt;sup>4</sup> Department of Chemistry, Simon Fraser University, Burnaby, Canada;

<sup>&</sup>lt;sup>5</sup> Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada;

<sup>&</sup>lt;sup>6</sup> John Ruedy Clinic, St, Paul's Hospital, Vancouver, Canada

<sup>&</sup>lt;sup>7</sup> AIDS Research Program, St. Paul's Hospital, Vancouver, Canada

<sup>&</sup>lt;sup>8</sup> Department of Medicine, University of British Columbia, Vancouver, Canada;

<sup>&</sup>lt;sup>9</sup> Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada;

<sup>&</sup>lt;sup>10</sup> Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre and Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

<sup>&</sup>lt;sup>11</sup> Department of Medicine, University of Ottawa, Ottawa, Canada

<sup>&</sup>lt;sup>12</sup> Ottawa Hospital Research Institute, Ottawa, Canada

<sup>&</sup>lt;sup>13</sup> School of Population and Public Health, University of British Columbia, Vancouver, Canada


<sup>&</sup>lt;sup>14</sup> CIHR Canadian HIV Trials Network, University of British Columbia, Vancouver, Canada

<sup>&</sup>lt;sup>15</sup> Centre for Health Evaluation and Outcome Sciences, Vancouver, Canada

<sup>&</sup>lt;sup>16</sup> Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada


<sup>&</sup>lt;sup>17</sup> Spectrum Health, Vancouver, Canada

<sup>&</sup>lt;sup>18</sup> Department of Family Practice, Faculty of Medicine, University of British Columbia, Canada



**Supplemental Figure 1: Humoral immune response measurements pre- and post-vaccination** *Panel A:* Binding antibody responses in COVID-19 naive PLWH (black circles), COVID-19 naive controls (grey circles) and COVID-19 convalescent individuals (colored as above) pre- and post-vaccination. Red dotted lines connect longitudinal measurements per participant. LLOD: assay lower limit of detection. ULOQ: assay upper limit of quantification. *Panel B:* Difference in log<sub>10</sub> binding antibody concentration between the first and second vaccine doses, with groups colored as above. P-values computed using the Mann-Whitney U test, and are uncorrected for multiple comparisons. *Panel C:* Same as A, except showing ACE2 displacement activity. Here, pre-vaccine measurements were only performed on a subset of 13 COVID-19 naive controls to estimate assay background, shown as grey shading. ND=not determined. *Panel D:* Same as B, except for ACE2 displacement activity.

## **Supplemental Figure 2**



**Supplemental Figure 2:** Correlation between nadir CD4+ T-cell count and humoral vaccine responses. *Panel A:* Correlation between nadir CD4+ T-cell count and binding antibody responses after one dose (red circles) and two doses (blue circles). Dotted lines are to help visualize the trend. *Panel B:* same as A, but for ACE2 displacement activity.